Peter Traber is the founder of Selecta Biosciences. Selecta Biosciences has raised $151M in total funding. Latest round: Series E.
Peter Traber is the Chief Medical Officer at Selecta Biosciences, a clinical-stage biotechnology company developing nanoparticle immunomodulatory drugs to overcome immune responses to biologic therapies. The company's proprietary ImmTOR platform and Synthetic Vaccine Particle (SVP) technology aim to induce antigen-specific immune tolerance. Selecta Biosciences has raised a total of $150.6 million across 8 funding rounds.
Full founder directory · Investor directory · Company funding database · Fundraising library